Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPR in Third or Later Line Therapy of DLBCL
NCT06832228Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Molecular Glues
- Countries
- 1
01
Overview
Open-label, single-arm trial of pomalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Overall Response Rate. Started Sep 2024; status: recruiting.
02
Drugs
pomalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06832228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832228.